ZUG, Switzerland, July 2, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced two recent additions to its U.S. intellectual property portfolio. The U.S. Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Application No. 14/448,999, titled "Methods for the Treatment of Tinnitus Induced by Cochlear Excitotoxicity," which will issue as U.S. Patent No. 9,072,662 on July 7, 2015. The patent's key claim is directed to the use of a pharmaceutical composition comprising Ketamine for reducing the perception of tinnitus; it is the third issued U.S. patent covering the use of AM-101 for the treatment of tinnitus.
In addition, the USPTO issued U.S. Patent No. 9,066,865 relating to methods of treating inner or middle ear diseases with intratympanic injections of poloxamer-based compositions. The claims are directed to the use of fluoroquinolone antibiotics in poloxamer 407 compositions under certain specifications. The patent is based on a continuation filing related to U.S. patent application 11/992,632, with priority date of September 28, 2005, which discloses the use of various biocompatible polymers for the controlled release of various active substances for the treatment of diseases of the inner or middle ear.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Help employers find you! Check out all the jobs and post your resume.
In addition, the USPTO issued U.S. Patent No. 9,066,865 relating to methods of treating inner or middle ear diseases with intratympanic injections of poloxamer-based compositions. The claims are directed to the use of fluoroquinolone antibiotics in poloxamer 407 compositions under certain specifications. The patent is based on a continuation filing related to U.S. patent application 11/992,632, with priority date of September 28, 2005, which discloses the use of various biocompatible polymers for the controlled release of various active substances for the treatment of diseases of the inner or middle ear.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Help employers find you! Check out all the jobs and post your resume.
